Click on the logos below to view more information. If you are interested to participate in IACAPAP 2020 as a Sponsor and/or Exhibitor please drop us an email at [email protected].
The Korean Academy of Child & Adolescent Psychiatry started as a research society in 1983, and was formally established as the Korean Academy of Child and Adolescent Psychiatry (KACAP) in 1986. Through annual academic conferences and publication of an English journal, we seek to promote research, education, and interaction among members, and to fundamentally contribute to the improvement of mental health in Korean children and adolescents.
Olayinka Olusola Omigbodun is Professor of Psychiatry and Pioneer Director of the University of Ibadan’s Centre for Child and Adolescent Mental Health (CCAMH). CCAMH is a multidisciplinary centre for training, research, advocacy and service in Child and Adolescent Mental Health (CAMH), which started with funding from the John D and Catherine T. MacArthur Foundation. Since training commenced in CCAMH in 2013, over 100 professionals from 14 countries in sub-Saharan Africa have completed an 18-month Master of Science degree programme in CAMH. Olayinka is also consultant in the Department of Child and Adolescent Psychiatry, University College Hospital (UCH), Ibadan, Nigeria and served as Pioneer Head from 1999-2017. Olayinka is a Past President of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). She is a Fellow of the Nigerian Academy of Science and a Foundation Fellow of the Nigerian Academy of Medicine. She presently leads several research projects aimed at improving access to CAMH services and ensuring policy development that will improve the well being of children and adolescents. She has over 100 journal articles and book chapters.
I graduated from Nippon Medical School in 1987, and in 1992 I joined Cornell Medical School, Westchester Division as a visiting fellow. In 1993, I embarked on a residency training program in psychiatry at Montefiore Medical Center/Albert Einstein College of Medicine, which I completed in 1997. I was then appointed Chief Resident and was charged with supervising the psychiatry residents. Subsequently, I became a research fellow, during which time I conducted clinical research and provided patient care at the Bronx Psychiatric Center. After completing my fellowship, I became a faculty member in the department. As a fellow, I pursued training in molecular genetics techniques and statistics. Over the years, I received research grants from the American Psychiatric Association and NARSAD that allowed me to work for the Basic Research Division in the Department of Psychiatry, where I focused particularly on identifying a genetic locus on chromosome 22q11 in multiple psychiatric disorders and neurodevelopmental disorders. In 2005, I returned to Nippon Medical School, Japan, where I established a child and adolescent clinic and focused on mood disorder and neurodevelopmental disorder. In 2014, I moved to Hokkaido University and started a new Department of Child and Adolescent Psychiatry.
Prof. Plener is the Chair of Child and Adolescent Psychiatry at the Medical University of Vienna, Austria and the head of the Department of Child and Adolescent Psychiatry at Vienna General Hospital since 2018. He has worked at the University hospital of Ulm (2005-2015) and the Central Institute for Mental Health in Mannheim, Germany (2016), before becoming deputy director and receiving a full professorship at the Department of Child and Adolescent Psychiatry at Ulm University, Ulm, Germany (2016-2018). Prof. Plener is member of the Austrian high council of health and of the executive board of the Austrian Society for Child and Adolescent Psychiatry. He is coordinator of the German clinical guidelines for Nonsuicidal Self-Injury (NSSI).
His research focus is on suicidality and NSSI in adolescents. Prof. Plener has conducted several studies in the fields of epidemiology and neurobiology of suicidality and NSSI. He received (among others) research funding from the German federal ministry of education and science (BMBF), the German research foundation (DFG), the Baden-Wuerttemberg Foundation and the Volkswagen Foundation adding to € 1.8 million. He has up to now published 140 papers in peer reviewed journals, three books and 42 book chapters.
Robert L. Hendren, D.O., is Professor of Psychiatry and Behavioral Science; Division of Child and Adolescent Psychiatry; Co-Director of the UCSF Dyslexia Center; Director, Program for Research On Neurodevelopmental and Translational Outcomes (PRONTO); Attending, STAR Center for ASD and NDD; Department of Psychiatry & Langley Porter Psychiatric Institute, UCSF Weill Institute for Neurosciences, University of California, San Francisco.
Dr. Hendren is Past President of the American Academy of Child and Adolescent Psychiatry (2007-2009). He has published well over 150 scientific papers and 5 books and has been listed in “The Best Doctors in America”, each year since it was first published in 1996. From 2001-2009, he was Professor of Psychiatry and Executive Director and Tsakopoulos-Vismara Chair at the University of California, Davis M.I.N.D. Institute (Medical Investigation of Neurodevelopmental Disorders).
His current areas of research and publication interests are translational interventional outcomes research including clinical pharmacology, nutraceutical and nutritional trials using biomarkers (metabolomics, measures of inflammation, oxidative stress, immune function, pharmacogenomics and neuroimaging) to enhance resilience in neurodevelopmental disorders.
Kai von Klitzing, MD, Professor of Child and Adolescent Psychiatry, University of Leipzig, Germany, Director of the Department of Child Psychiatry, Psychotherapy and Psychosomatics at the Leipzig University Medical Center; visiting professor at the Sapienza University in Rome, psychoanalyst for children, adolescents, and adults, Past- President of the World Association for Infant Mental Health (WAIMH), Editor of the Journal Kinderanalyse/Child Analysis, Associate- editor of the Infant Mental Health Journal. Scientific interests: Developmental psychopathology, infant psychiatry, children’s narratives, psychotherapy research, childhood maltreatment, and biological stress regulation. Books on attachment disorder, children of immigrant families, child psychotherapy.
Cecilia A. Essau is Professor of Developmental Psychopathology, and Director of Centre for Applied Research and Assessment in Child and Adolescent Wellbeing at the University of Roehampton, UK. She is also a scientific advisor to the United Nations Office on Drugs and Crime project on “Treatnet Family Intervention” for adolescents with drug use disorders.
Prof Essau, born and raised in Sarawak, obtained her undergraduate and Master of Arts degree from Lakehead University (Canada), PhD from the University of Konstanz (Germany), and “Habilitation” (requirement to apply for tenure-track full professorships in Germany) in Clinical Psychology from the University of Bremen (Germany).
Prof Essau has Visiting Chairs at numerous universities, including the Norman Munn Distinguished Visiting Scholar at Flinders University, the Florey Medical Research Foundation Mental Health Visiting Professor at the University of Adelaide, and a Distinguished Visiting Professorship at De La Salle University. In 2011, she was made Fellow of the British Psychological Society in recognition of her contribution to the field of Psychology. Cecilia is also Fellow of the Japan Society for the Promotion of Science.
She is the author of 230 articles, and is the author/editor of 21 books in the area of youth mental health.
Prof Christel Middeldorp has a conjoint appointment with the Child Health Research Centre (CHRC), UQ, and Child and Youth Mental Health Service (CYMHS), Children’s Health Queensland Hospital and Health Services (CHQ HHS). She is also affiliated with the Department of Biological Psychology, Vrije Universiteit Amsterdam, The Netherlands.
The large burden of disease by mental disorders is partly due to the sometimes chronic course. Her aim is to improve prognosis by providing targeted treatment for children and families at high risk for persistent symptoms. To that end, her research focuses on 1) improving recognition of children that are at higher risk for a chronic course and, following up on these findings 2) developing targeted treatment to prevent this unfavourable course.
Christel is the PI of CAPICE: Childhood and Adolescence Psychopathology, unravelling the complex etiology by a large Interdisciplinary Collaboration in Europe, funded by an EU Marie Curie grant, coordinated by the Vrije Universiteit Amsterdam. This project aims to identify genetic variants underlying the development and persistence of common childhood psychopathology by using data from population based longitudinal child and adolescent cohorts from over the world. Many of these cohorts participate in the Early Genetics and Lifecourse Epidemiology (EAGLE) Consortium.
This research is complemented by studies in clinical populations. She established a clinical cohort of families with children with neurodevelopmental disorders. They are followed longitudinally to identify factors, including biomarkers influencing outcome. It is also investigated whether providing integrated care to parents and children improves outcomes. She also analyses the data as collected in electronic health records in the Child and Youth Mental Health Services to gain knowledge on treatment outcomes in the services and characteristics of the child, family and their circumstances thata are associated with these outcomes.
In 2019, Christel was appointed by the federal government as Co-Chair of the Childhood Mental Health and Wellbeing Strategy Working Party. The working group is developing a strategy which will provide a framework that embeds protective skills in early childhood, creates mentally healthy home environments, supports parents, and prevents or treats early childhood trauma.
Professor Eapen is Chair of Infant, Child and Adolescent Psychiatry at UNSW Sydney, Head of the Academic Unit of Child Psychiatry South West Sydney (AUCS), and Director of BestSTART South West Sydney child health unit. She started her academic career at University College London after completing her graduate training in India and postgraduate training in Child Psychiatry through the Great Ormond Street Hospital Training Scheme, London, and PhD research at the National Hospital for Neurology & Neurosurgery, Queen Square, University of London. Her clinical and research interests centre on issues of early development and neurodevelopmental disorders including Tourette Syndrome and autism. She has authored around 300 scientific publications. She is a member of several international consortiums including Obsessive Compulsive Foundation Genetics Collaborative, Homozygosity Mapping Collaborative for Autism and Psychiatric Genomics Consortium. She is part of several collaborative grants with over $30 million in funding including from National Health and Medical Research Council (NHMRC), Australian Research Council (ARC), and Co-operative Research Centre for autism where she is a Program Director. She leads the Clinical Academic Group on “Early Life Determinants of Health (ELDoH)” under the Sydney Partnership for Health Education Research and Enterprise (SPHERE), an NHMRC accredited Advanced Health Research and Translation Centre (AHRTC).
Orient EuroPharma (OEP), a well-rounded & multinational pharmaceutical company founded in 1982 and officially listed on the Taipei Exchange since 2003. OEP’s major business focuses on prescription medicines, nutricare and anti-aging. Furthermore, established subsidiary companies, OrientPharma and OP NanoPharma, to develop and manufacture new drugs to meet real human needs. The Company is committed to providing products and services that are valuable and unique. Through vertical integration, OEP provides clients with more comprehensive services, from clinical trial to marketing, and always striving to strategize in innovative fields, cultivating markets in the Asia Pacific and the US, and is working towards the goal of being the “Benchmark Enterprise in the Asia Pacific Region.
We are Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on our diverse footprint in ASEAN countries. In part of our vision to provide a better quality of life to patients, we are constantly on the pulse of our industry’s innovation to meet patients’ needs. Hyphens Pharma is a part of the Hyphens Group.
Listed on the Catalist board of Singapore Exchange (SGX).
Break the Stigma for Families (BtSfF) is an initiative centred on bicycles and cycling, aimed to spread the message that children’s mental illnesses are a family affair, and that families not only suffer together, but more importantly, heal and grow together. BtSfF seeks to inform its local host communities that children’s mental illnesses are real, common, treatable and preventable; to help destigmatise these conditions and make them open for discussion. BtSfF celebrates the role of family, friends and community in the healing process.
BtSfF started in the Netherlands in 2018, has since had meetings in the United States, Netherlands and Stockholm, Sweden. A signature event in 2020, BtSfF Singapore, will take place on Saturday, July 18, in anticipation of the IACAPAP World Congress, which will start that Monday (the 20th). The BtSfF event involves a closed group of cyclists who will complete a cycling trail around Singapore, with the endpoint being the Institute of Mental Health where a mental health carnival that is open to the general public will be held.
Routledge is the world’s leading academic publisher in the Humanities and Social Sciences. Routledge publishes a comprehensive portfolio of books, journals and other resources on Counseling, Child & Adolescent Mental Health, Clinical Psychology & Psychiatry, Psychotherapy, and more topics in Mental Health, serving scholars, instructors, and professional communities worldwide.